On December 20, 2024, the FDA approved Zepbound (tirzepatide) as the first and only prescription medication for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. This makes Zepbound the only drug in history to be approved specifically for OSA — a condition that affects an estimated 30 million Americans and has, until now, been
GLP-1 weight loss medications have evolved from ~15% weight loss with semaglutide (Wegovy 2.4 mg) to ~20%+ with higher-dose semaglutide (7.2 mg) and dual agonists like tirzepatide (Zepbound). Tirzepatide still shows slightly higher peak results, but high-dose Wegovy significantly narrows the gap, giving clinicians two viable paths to achieve near–bariatric-level weight loss. The Big Shift:
If you’re considering Zepbound (tirzepatide) for weight management, understanding its potential side effects is essential for making an informed decision. This FDA-approved medication has helped many patients achieve significant weight loss, but like all medications, it comes with considerations you should discuss with your healthcare provider. At BeLite Medical Center, we believe informed patients are
If you’re considering Zepbound (tirzepatide) for weight loss, you’re probably wondering: when do you see results with Zepbound? Understanding the Zepbound results timeline can help set realistic expectations and keep you motivated throughout your weight loss journey. When Do You See Results with Zepbound? The short answer: most people begin noticing Zepbound first month results,
When people think about weight loss, they usually picture smaller clothes, lower blood pressure, or better blood sugar. What often gets less attention is something patients repeatedly tell clinicians: “I just want to feel better in my body and in my life — including in bed.” PubMed-indexed research backs this up: clinically meaningful weight loss
In May 2025, the New England Journal of Medicine published the first head-to-head clinical trial comparing two of the most effective anti-obesity medications on the market: tirzepatide (Zepbound) and semaglutide (Wegovy). This was the phase 3b open label extension of the SURMOUNT-5 clinical trial involving 751 non-diabetic obese patients. The main finding was that tirzepatide led to significantly more weight loss than semaglutide over 72
